No EU Fast Track for AZ’s Imfinzi In Stage III Lung Cancer
AstraZeneca will be disappointed at the European Medicines Agency’s refusal of its request for accelerated assessment of Imfinzi in earlier-stage lung cancer as the company is aiming to take hold of this new indication and run with it.
You may also be interested in...
Important US filing goes ahead as AstraZeneca submits sBLA for Imfinzi in earlier-stage non-small cell lung cancer.
The European Medicines Agency recently denied AstraZeneca’s pre-filing request for accelerated assessment of Imfinzi in Stage III NSCLC, an indication the company is hoping to make its own. It’ll be no consolation that the EMA this year seems to have rejected as many fast-track requests as it has granted.
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.